Retraction: Zhang D, Zhang Y, Sun X. LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1. Asia-Pac J Clin Oncol. 2021;17:253-263. https://doi.org/10.1111/ajco.13451. The above article, published online on 20 October 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editors-in-Chief, Professor Stephen Ackland and Professor Mengzhao Wang, and John Wiley & Sons Australia, Ltd. Following publication, concerns were raised by third parties regarding possible image duplication within Figures 2, 4 and 6. Upon investigation by the editorial team, it was concluded that several image elements of the experimental data were duplicated within figures in the article, or had already been published elsewhere in a different scientific context. Thus, the editors consider the conclusions of this article to no longer be reliable.
撤稿:张丹，张颖，孙鑫。LINC01133通过调控miR-30a-5p/FOXD1促进宫颈癌的进展。中华临床医学杂志，2011;17(2):563 - 563。https://doi.org/10.1111/ajco.13451。上述文章于2020年10月20日在线发表在Wiley在线图书馆(wileyonlinelibrary.com)上，经该杂志主编Stephen Ackland教授和Mengzhao Wang教授以及John Wiley & Sons Australia, Ltd.同意撤回。出版后，第三方对图2、图4和图6中可能出现的图像重复表示关注。经过编辑团队的调查，得出的结论是，实验数据的几个图像元素在文章中的数字中重复，或者已经在其他地方发表在不同的科学背景下。因此，编辑认为本文的结论不再可靠。
{"title":"Retraction: LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1","authors":"","doi":"10.1111/ajco.13997","DOIUrl":"10.1111/ajco.13997","url":null,"abstract":"<p><b>Retraction</b>: Zhang D, Zhang Y, Sun X. LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1. <i>Asia-Pac J Clin Oncol</i>. 2021;17:253-263. https://doi.org/10.1111/ajco.13451. The above article, published online on 20 October 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editors-in-Chief, Professor Stephen Ackland and Professor Mengzhao Wang, and John Wiley & Sons Australia, Ltd. Following publication, concerns were raised by third parties regarding possible image duplication within Figures 2, 4 and 6. Upon investigation by the editorial team, it was concluded that several image elements of the experimental data were duplicated within figures in the article, or had already been published elsewhere in a different scientific context. Thus, the editors consider the conclusions of this article to no longer be reliable.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.13997","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Author Listing","authors":"","doi":"10.1111/ajco.14027","DOIUrl":"https://doi.org/10.1111/ajco.14027","url":null,"abstract":"<p>Abo, S 237,59</p><p>Abousamra, A 433</p><p>Ackerman, I 253</p><p>Ackland, T 53</p><p>Adam, T 358</p><p>Adams, C 139</p><p>Adams, D 377</p><p>Adams, G 233</p><p>Adams, J 254</p><p>Adams, K 188</p><p>Adderley, H 42</p><p>Adlard, KN 198</p><p>Aga, A 189</p><p>Agar, M 164,356,433,434,450,451,452,514</p><p>Agar, MR 497</p><p>Ahern, E 305,306</p><p>Ahmadi, N 170,170,171,171</p><p>Ahmed, E 243</p><p>Ahn, M 199</p><p>Aitken, J 104,50</p><p>Aitken, JF 501</p><p>Akechi, T 491</p><p>Akhurst, T 515</p><p>Al Deleemy, M 219</p><p>Al-Mufti, T 300,318</p><p>Alamgeer, M 221</p><p>Alexander, H 314</p><p>Alexander, M 129,131,132</p><p>ALHulais, R 172</p><p>Allan, C 419</p><p>Allan, R 427</p><p>Allard, N 411</p><p>Allen, C 423</p><p>Allen, M 516</p><p>Allen, S 173</p><p>Alonso, M 200</p><p>Alsaid, H 78</p><p>Aly, A 180,187</p><p>Amgarth-Duff, I 450,497,514</p><p>Amil, A 415</p><p>Ananda, S 189</p><p>Anazodo, A 483</p><p>Andersen, S 407</p><p>Anderson, D 513</p><p>Anderson, H 288</p><p>Anderson, LE 160</p><p>Anderson, M 302</p><p>Anderson, W 30</p><p>Andree-Evarts, D 163,421,423</p><p>Andrew, C 449</p><p>Andrews, J 82</p><p>Angioli, R 174</p><p>Antill, YC 82</p><p>Antony, J 277</p><p>Arance, A 209</p><p>Aranda, S 83</p><p>Arendse, M 302</p><p>Arif, S 388</p><p>Ariyarathna, D 173</p><p>Arkadieff, K 416</p><p>Arneil, M 212</p><p>Arnolda, G 374</p><p>Arora, S 61</p><p>Arrington, D 263</p><p>Arulananda, S 178</p><p>Asadi, K 189</p><p>Ascierto, PA 209</p><p>Ashford, B 482</p><p>Ashwell, C 463</p><p>Ashwell, W 273</p><p>Aslam, M 301</p><p>Athan, S 128,129</p><p>Atkinson, V 212</p><p>Au-Yeung, G 117,364</p><p>Auchettl, J 412</p><p>Austen, M 93</p><p>Austin, E 373</p><p>Avery, S 194,370</p><p>Aye, P 302</p><p>Ayre, S 320</p><p>Ayub, Z 42</p><p>Aziez, A 78</p><p>Bagga, R 161</p><p>Bailey, E 74</p><p>Bailey, H 182</p><p>Bairstow, P 189</p><p>Baker, S 292</p><p>Baksa, S 429</p><p>Balaam, S 513</p><p>Balabhadrapatruni, C 78</p><p>Balachander, S 79</p><p>Balana, C 200</p><p>Baldwin, C 207</p><p>Ball, D 211</p><p>Ballinger, M 402</p><p>Bamgboje-Ayodele, A 277</p><p>Banerjee, A 174,78</p><p>Bang, A 23</p><p>Banks, E 52</p><p>Bansal, S 233</p><p>Baramidze, A 503</p><p>Bardia, A 248</p><p>Bareham, M 440,476</p><p>Barker, S 22</p><p>Barnes, J 302</p><p>Barnes, T 251</p><p>Barnett, F 333,395</p><p>Baron, A 216</p><p>Baron-Hay, S 196</p><p>Barratt, A 258</p><p>Barrios, C 248</p><p>Barry, JA 78</p><p>Bartle, J 510</p><p>Bartlett, S 281</p><p>Bartley, N 321,390</p><p>Barton, C 284</p><p>Barton, M 481,59</p><p>Bartula, I 424</p><p>Bastick, P 184</p><p>Bauer, J 208</p><p>Bauer, JD 164,239</p><p>Bauerschlag, D 174</p><p>Baxi, S 490</p><p>Baxter, K 412</p><p>Bayes, S 369</p><p>Beale, GK 175</p><p>Beaton, S 441</p><p>Beaton, SS 442</p><p>Beattie, A 136</p><p>Beatty, L 134,166,261,277,312,383,445,467,473</p><p>Beaven, C 176,177</p><p>Bechelli, M 178</p><p>Bejjani, C 433</p><p>Bekaii-Saab, T 101</p><p>Bell, K 164,243</p><p>Bell, R 133</p><p>Bellmunt, J 241</p><p>Benge, S 513</p><p>Bennett, G ","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68180156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Decisions and prompts to screen for cervical, bowel, and breast cancer abs# 160
Shalmoli Bhattacharyya
Cancer-associated mesenchymal stem cells promote proliferation in chemo-radio-resistant cervical cancer cells abs# 161
Carina Chan
Identifying MET exon 14 skipping mutations in squamous cell lung cancer patients abs# 162
Zoe Clarke
Medical imaging simulated radiation therapy: Improving access to palliative radiation therapy in WNSWLHD abs# 163
Merran Findlay
Dashboards to deliver data-driven dietetics in the digital age: Translation of evidence-based nutrition guidelines into practice abs# 164
Subhash Gupta
Emerging therapeutic potential of Vardhamana Pippali Rasayana (Ayurvedic drug) in breast cancer abs# 165
Morgan Leske
Feasibility and preliminary efficacy of brief coaching calls in Healthy Living after Cancer Online: A randomized control trial abs# 166
Ashley Macleod
Investigating LGBTIQA+ Inclusion in Victorian Cancer Care: An incomplete picture abs# 167
Georgios Mavropalias
Implementation of eccentric exercise programs as therapy during cancer – A scoping review abs# 168
Geoffrey Yuet Mun Wong
Genomic profiling and biomarker discovery for predicting early intrahepatic recurrence following resection of colorectal liver metastases abs# 169
Navid Ahmadi
Perioperative and oncological outcomes of patients undergoing post-chemotherapy robotic-retroperitoneal lymph node dissection for management of primary testicular cancer abs# 170
Navid Ahmadi
Perioperative and oncological outcomes of patients undergoing primary robotic-RPLND for management of primary testicular cancer abs# 171
Reem ALHulais
Efficacy of celecoxib as an anticancer drug examined in the murine CT26 metastatic colorectal cancer model abs# 172
Dinuka Ariyarathna
Providing early access to geriatric oncology services in a regional cancer center – An evaluation of a newly established Nurse-Navigator led Geriatric Oncology Service Model and associated safety outcomes abs# 173
Ashish Banerjee
Dostarlimab for Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): Outcomes by Blinded Independent Central Review (BICR) of the RUBY trial abs# 174
Greta K Beale
Association between clinical outcomes and PSMA PET metrics in patients with metastatic prostate cancer abs# 175
Cassie Beaven
Immunotherapy in the setting of metastatic cutaneous squamous cell carcinoma – An OncoGeriatrics Perspective abs# 176
Cassie Beaven
An evaluation of time to treatment with adjuvant chemotherapy in high-risk early breast cancer patients in a r
Leah Zajdlewicz决定和提示筛查宫颈、肠道、，和癌症abs#160Shalmoli BhattacharyyaCancer-associated间充质干细胞促进化疗耐药宫颈癌症细胞的增殖abs#161Carina Chan识别鳞状细胞肺癌癌症患者的MET外显子14跳跃突变abs#162 Zoe Clarke医学成像模拟放射治疗：改善WNSWLHD患者接受姑息性放射治疗的机会abs#163Merran FindlayDashboards在数字时代提供数据驱动的营养学：将循证营养指南转化为实践abs#164 Subhash Gupta Vardhamana Pippali Rasayana（阿育吠陀药物）在乳腺癌症中的治疗潜力abs#165 Morgan Leske癌症后健康生活中简短辅导电话的可行性和初步效果在线：随机对照试验abs#166Ashley MacleodInvestigating LGBTIQA+Inclusion in Victorian癌症护理：一张不完整的照片abs#167Georgios Mavropalias在癌症期间实施偏心运动计划作为治疗——范围审查abs#168 Geoffrey Yuet-Mun Wong预测结直肠癌切除后早期肝内复发的基因组分析和生物标志物发现转移abs#169Navid Ahmadi接受化疗后机器人-腹腔淋巴结清扫治疗原发性睾丸癌症的患者的围手术期和肿瘤结果abs#170Navid Ahmedi接受原发性机器人-RPLND治疗原发期睾丸癌症的患者的术中和肿瘤结果abs#171Reem ALHulais塞来昔布作为一种在小鼠CT26转移性结直肠癌癌症模型中检查的抗癌药物abs#172Dinuka Ariyarathna在癌症地区中心提供早期老年肿瘤服务——对新建立的Nurse-Navigator领导的老年肿瘤服务模型和相关安全性结果的评估abs#173Ashish Banerjee Dostarlimab用于原发性晚期或复发（a/R）子宫内膜癌症（EC）：RUBY试验盲独立中心审查（BICR）的结果abs#174Greta K Beale转移性前列腺癌症患者的临床结果和PSMA PET指标之间的关联abs#175Cassie Beaven转移性皮肤鳞状细胞癌背景下的免疫治疗——肿瘤老年医学视角abs#176Cassie Beane时间评估在区域环境中对高危早期癌症乳腺癌患者进行辅助化疗abs#177Maria Bechelli改善试验的机会：一种用于识别招募患者的快速病例确定工具abs#178Anish Bhattacharya 18F-FDG PET/CT在小儿肉瘤的初始分期和治疗计划中的作用abs#179 Jaimee CaciPrehabilitation改善食管-胃癌症手术前的营养和肌肉参数abs#180Cian病例PET/CT经皮活检对可疑腹膜后肉瘤的诊断功效abs#181 Felicity病例Real-world疾病特征、测试模式、，澳大利亚RET融合阳性晚期非小细胞肺癌癌症的一线治疗abs#182David Chen接受胆道切除术的肿瘤患者围手术期因素与DAH30之间的关联：一项回顾性队列研究abs#183Kar Ven Cavan ChowReal-world颅外结果和实践，性腺外生殖细胞肿瘤：澳大利亚iTestis数据库的回顾性分析abs#184Udari Colombage盆底肌肉训练治疗癌症妇女尿失禁的可行性：远程健康干预试验abs#185Jermaine Coward AdvanTIG-105:检查点抑制剂（CPI）患者中ociperlimab+tislelizumab的1b期剂量扩展研究-经历过晚期非小细胞肺癌癌症（NSCLC）abs#186Kate Crombie康复减少了食管胃癌症手术后的术后并发症abs#187Letta D’Costa什么是“真正的种族主义”——医护人员对种族和种族主义的认知abs#188Bianka D’souzaHER2在晚期癌症中的检测——了解并减少当前改善患者结果公平性的实践abs#189 Daphne DayA口服完全雌激素受体（ER）拮抗剂（CERAN）和选择性ER降解剂（SERD）OP-1250在晚期或转移性ER-阳性、HER2-阴性癌症（MBC）患者（pts）中的1b/2期研究abs#190 Daphne DayA OX40激动剂BGB-A445的1期（Ph1）研究，抗PD-1单克隆抗体（mAb），在晚期实体瘤患者中腹肌#191乔治亚·德安布罗斯一例脸颊原发性皮肤边缘区B细胞淋巴瘤腹肌#192克里斯汀·迪克斯特拉解决未知的原发性癌症（SUPER）：一项队列研究——数字化和适应挑战腹肌#193海莉·T·狄龙运动和久坐行为联合干预在接受手术的成年人中保留了VO2峰值
{"title":"Poster Listing","authors":"","doi":"10.1111/ajco.14024","DOIUrl":"10.1111/ajco.14024","url":null,"abstract":"<p><b>Leah Zajdlewicz</b></p><p>Decisions and prompts to screen for cervical, bowel, and breast cancer <i>abs# 160</i></p><p><b>Shalmoli Bhattacharyya</b></p><p>Cancer-associated mesenchymal stem cells promote proliferation in chemo-radio-resistant cervical cancer cells <i>abs# 161</i></p><p><b>Carina Chan</b></p><p>Identifying MET exon 14 skipping mutations in squamous cell lung cancer patients <i>abs# 162</i></p><p><b>Zoe Clarke</b></p><p>Medical imaging simulated radiation therapy: Improving access to palliative radiation therapy in WNSWLHD <i>abs# 163</i></p><p><b>Merran Findlay</b></p><p>Dashboards to deliver data-driven dietetics in the digital age: Translation of evidence-based nutrition guidelines into practice <i>abs# 164</i></p><p><b>Subhash Gupta</b></p><p>Emerging therapeutic potential of Vardhamana Pippali Rasayana (Ayurvedic drug) in breast cancer <i>abs# 165</i></p><p><b>Morgan Leske</b></p><p>Feasibility and preliminary efficacy of brief coaching calls in Healthy Living after Cancer Online: A randomized control trial <i>abs# 166</i></p><p><b>Ashley Macleod</b></p><p>Investigating LGBTIQA+ Inclusion in Victorian Cancer Care: An incomplete picture <i>abs# 167</i></p><p><b>Georgios Mavropalias</b></p><p>Implementation of eccentric exercise programs as therapy during cancer – A scoping review <i>abs# 168</i></p><p><b>Geoffrey Yuet Mun Wong</b></p><p>Genomic profiling and biomarker discovery for predicting early intrahepatic recurrence following resection of colorectal liver metastases <i>abs# 169</i></p><p><b>Navid Ahmadi</b></p><p>Perioperative and oncological outcomes of patients undergoing post-chemotherapy robotic-retroperitoneal lymph node dissection for management of primary testicular cancer <i>abs# 170</i></p><p><b>Navid Ahmadi</b></p><p>Perioperative and oncological outcomes of patients undergoing primary robotic-RPLND for management of primary testicular cancer <i>abs# 171</i></p><p><b>Reem ALHulais</b></p><p>Efficacy of celecoxib as an anticancer drug examined in the murine CT26 metastatic colorectal cancer model <i>abs# 172</i></p><p><b>Dinuka Ariyarathna</b></p><p>Providing early access to geriatric oncology services in a regional cancer center – An evaluation of a newly established Nurse-Navigator led Geriatric Oncology Service Model and associated safety outcomes <i>abs# 173</i></p><p><b>Ashish Banerjee</b></p><p>Dostarlimab for Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): Outcomes by Blinded Independent Central Review (BICR) of the RUBY trial <i>abs# 174</i></p><p><b>Greta K Beale</b></p><p>Association between clinical outcomes and PSMA PET metrics in patients with metastatic prostate cancer <i>abs# 175</i></p><p><b>Cassie Beaven</b></p><p>Immunotherapy in the setting of metastatic cutaneous squamous cell carcinoma – An OncoGeriatrics Perspective <i>abs# 176</i></p><p><b>Cassie Beaven</b></p><p>An evaluation of time to treatment with adjuvant chemotherapy in high-risk early breast cancer patients in a r","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Empowering excellence: advancing the quality and safety of gynaecological cancer care in Queensland
Chair: Rhett Morton
7:00 AM Rhett Morton
Navigating the pathways: Patterns of care for all women with gynaecological cancer in Queensland abs# 1
7:15 AM Tamara Butler
Ensuring equity: Monitoring health outcomes for Queensland First Nations women with cervical and endometrial cancer abs# 2
7:30 AM Penny Mackenzie
Trends in the utilisation of brachytherapy in cervical cancer in Queensland: How do we compare? abs# 3
7:45 AM Shaun McGrath
Increased endometrial cancer rates: The link between obesity and endometrial cancer risk abs# 4
Session sponsored by
Innovations in Implementing Nutrition and Exercise Evidence to Enhance Cancer Care and Outcomes
Co-Chair: Jenelle Loeliger
Co-Chair: David Mizrahi
This session will include interactive Q&A with all speakers.
This breakfast session is sponsored by COSA, and delivered by the COSA Nutrition and Exercise and Cancer Groups
Best of the Best Posters – Epidemiology
Chair: Ashley Hopkins
Discussant: Rebecca Venchiarutti
7:15 AM Maria Aslam
Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: A population-based cohort study abs# 301
7:20 AM Vicki Durston
Making metastatic breast cancer count: Barriers, enablers and key recommendations identified through expert interviews and a national roundtable abs# 304
7:25 AM Lucy Gately
Linking data from a brain cancer clinical registry (BRAIN) with the state-based registry of Births Deaths Marriages: Improving the quality of clinical registry survival data abs# 305
7:30 AM Huah Shin Ng
Patterns of mental health service utilisation in people with cancer compared with people without cancer: The Australian National Study of Mental Health and Wellbeing analysis abs# 312
7:35 AM Suzanne Poulgrain
Patterns of treatment and survival outcomes for people diagnosed with glioblastoma: A population-based study in Queensland abs# 314
7:40 AM Robert Power
Modifiable risk factors for cancer among people with Lynch syndrome: An international, cross-sectional survey abs# 315
7:45 AM Euan Walpole
Benchmarking statewide cancer data: A comparison of breast and gynaecological cancer care indicators between Victoria and Queensland abs# 316
Session sponsored by
Best of the Best Posters – Clinical Research & Supportive Care
Chair: Laura Kirsten
Discussant: Desmond Yip
7:15 AM Morgan Farley
abs#2711:15 AM Norah Finn与最佳护理途径的早期检测阶段相一致与改善癌症妇女的预后有关abs#2811:30 AM Caitlin I Fox-Harding乳腺癌相关淋巴水肿的高负荷与低负荷耐力运动：一项随机对照试验abs#2911:45 AM Yada Kanjanapa癌症患者的现实世界分析符合辅助CDK4/6抑制剂的资格abs#3012:00 PM Antonia Pearson癌症妇女的泌尿生殖系统症状：患者的态度和经历abs#3112:15 PM Kate Webber实时患者报告结果测量（PROM）对癌症乳腺癌患者急诊科表现的影响abs#32午餐由在老年肿瘤学中回答这些老年问题下午1:30 Etienne Brain研究癌症的人口统计学转变（国际和学术合作的想法）abs#331:50 PM Heather Lane老年肿瘤学：老年医生的作用abs#342:05 PM Michael Krasovitsky照顾癌症老年人：医学肿瘤学家的聚会abs#352:20 PM Polly Dufton护理和联合健康在护理患有癌症的老年人中的作用abs#362:35 PM小组讨论由癌症相关淋巴水肿赞助的会议：从预防到管理主席：Sandi Hayes4:00 PM Melanie Plinsinga淋巴水肿有多大问题？腹肌#337:17 PM Louise Koelmeyer预防淋巴水肿的探索腹肌#384:34 PM Hildegard Reul-Hiche减少淋巴水肿的影响：通过手术方法进行保守管理腹肌#394:51 PM Kira Bloomquist运动和体重管理对癌症相关淋巴水肿的影响腹肌#405:08 PM Debbie Geyer消除淋巴水肿管理中的神话腹肌#415:25 PM小组讨论医学问题主席：Chi Hao La4:00 PM Faye Coe先前治疗线的平均持续时间预测艾瑞布林化疗对转移性乳腺癌癌症患者的临床益处abs#424:20 PM Gail Rowan癌症中新出现的抗体药物偶联物abs#434:40 PM Peter Savas在乳腺癌中利用免疫系统abs#445:00 PMOlivia SmibertMedicines and the microbiome abs#45消除癌症宫颈癌战略：澳大利亚的成功故事激励全球行动主席：Marion Saville4:00 PM Karen Canfell澳大利亚和全球战略概述abs#464:15 PM Julia Brotherton提高疫苗接种和筛查率的实施策略？abs#474:30 PM Lisa Whop在土著和托雷斯海峡岛民社区实现消除宫颈癌症abs#484:45 PM Farhana SultanaHPV在澳大利亚的宫颈筛查：项目中的自我收集和随访abs#495:00 PM小组讨论最佳口头陈述-支持性护理主席：Belinda SteerDiscussant:Michael Jefford4:00PM Louisa Gordon原发性脑瘤患者远程健康心理支持干预的成本效益分析：远程健康对脑瘤的意义腹肌#504:15 PM Lauren Ha致力于更好地评估身体活动和久坐行为：一种使用腕关节加速度计对儿童癌症幸存者进行新的聚类分析方法腹肌#514:30 PM Bogda与癌症相关的KoczwaraPain及其对日常生活的干扰：对16053名癌症幸存者和106345名癌症未患者进行的基于人群的比较研究。澳大利亚维多利亚州吉普斯兰市农村癌症幸存者的财务毒性（abs#535:00 PM Eli Ristevski）abs#545:15 PM Eva YuenDoes护理人员和癌症患者的健康素养、社会支持和联系影响护理人员的心理发病率？abs#55最佳口头演讲-健康服务I主席：Wei-Sam LamDiscussant:Kim Hobbes4:00 PM Jennifer Cohere一项由父母主导的计划，旨在促进癌症后儿童的健康饮食习惯：一项随机对照试验。 腹肌#564:15 PM Prue Cormie锻炼对话：一项混合方法研究，解释了健康专业人员需要将锻炼建议嵌入癌症常规护理腹肌#574:30 PM Suzanne Grant培训医疗口译员关于癌症临床试验腹肌#584:45 PM Ella Sexton和Hannah Ray利用共同设计的头部资源实施护理的康复模型正在接受放射治疗的癌症患者腹肌#595:00 PM Shalini VinodLung癌症（基于互联网）Delphi（LuCiD）：建立澳大拉西亚胸部肿瘤学临床质量指标的改良eDelphi共识腹肌#605:15 PM Haitham Tuffaha前列腺癌症基因检测共识建议：Delphi研究腹肌#61 COSA高级学员晚宴：关于如何治疗高危早期癌症的完整指南-从我们的专家那里获得多学科团队的观点主席：Belinda Yeo本次晚宴特别适合我们在癌症管理任何专业的受训人员。我们将听取关于如何治疗高危早期癌症的重要外科、整形、放射和医学肿瘤学观点。患者和临床医生面临的挑战是，要做出这些知情的决定，需要制定什么样的治疗、按照什么顺序以及什么样的成像和病理信息。我们期待着一个有趣的夜晚，与您在乳腺癌症护理相关学科的同事见面！这次会议由诺华公司资助。内容和议程由COSA和医学专家独立制定。癌症药剂师晚宴-走向药剂师处方：满足我们患者的需求Co-Chair：Marissa RyanCo-Chair:Kimberly-Ann Kerr癌症药剂师处方-我们正在接近吗？药剂师已经在积极为癌症患者在入院前、治疗和出院或过渡计划期间提供优质护理。临床药剂师的角色已经演变，药剂师在审查患者的药物相关问题后，为医疗团队提供有价值的建议。虽然在社区环境中有一些建议和试验举措，但澳大利亚的药剂师处方目前非常有限。相比之下，药剂师自2003年以来一直在英国开处方。他们是如何做到这一点的？我们能从英国的同事那里学到什么？药剂师处方医生面临哪些挑战？在本次研讨会上，我们将讨论英国模式、其运作方式以及澳大利亚正在进行的高级药剂师实践，包括合作药剂师药物图表（PPMC）。PPMC模式已在维多利亚州的普通医学和最近的肿瘤学环境中进行了测试和实施。在PPMC模式下，药剂师被置于一个独特的位置，可以审查、记录药物并与处方医生共同制定药物图表。PPMC是向药剂师处方和高级实践迈出的一步吗？这会成为药剂师开处方的依据吗？我们如何才能建立高级执业药剂师模式？由Fight with care赞助的会议-科学指南和合作伙伴关系，以改善因癌症治疗而产生皮肤毒性的患者的治疗机会主席：Victoria MarFight with care副教授是La Roche Posay的新项目，旨在强调在治疗肿瘤治疗副作用时采用整体方法的重要性。我们欢迎您与活动背后的科学专家一起参加我们的晚会，围绕肿瘤患者皮肤毒性的治疗指南和管理进行讨论，并了解我们与麦格拉斯基金会合作所做的工作，以推动因癌症治疗而出现皮肤毒性的患者更好地获得治疗。皮肤毒性与护理抗争计划启动，包括。亚历山大公主医院的肿瘤病科诊所由Age赞助的
{"title":"Program in Detail","authors":"","doi":"10.1111/ajco.14023","DOIUrl":"10.1111/ajco.14023","url":null,"abstract":"<p>\u0000 \u0000 </p><p><b>Empowering excellence: advancing the quality and safety of gynaecological cancer care in Queensland</b>\u0000 \u0000 </p><p>Chair: Rhett Morton</p><p>7:00 AM <b>Rhett Morton</b></p><p>Navigating the pathways: Patterns of care for all women with gynaecological cancer in Queensland <i>abs# 1</i></p><p>7:15 AM <b>Tamara Butler</b></p><p>Ensuring equity: Monitoring health outcomes for Queensland First Nations women with cervical and endometrial cancer <i>abs# 2</i></p><p>7:30 AM <b>Penny Mackenzie</b></p><p>Trends in the utilisation of brachytherapy in cervical cancer in Queensland: How do we compare? <i>abs# 3</i></p><p>7:45 AM <b>Shaun McGrath</b></p><p>Increased endometrial cancer rates: The link between obesity and endometrial cancer risk <i>abs# 4</i></p><p><i>Session sponsored by</i>\u0000 </p><p><b>Innovations in Implementing Nutrition and Exercise Evidence to Enhance Cancer Care and Outcomes</b>\u0000 \u0000 </p><p>Co-Chair: Jenelle Loeliger</p><p>Co-Chair: David Mizrahi</p><p>This session will include interactive Q&A with all speakers.</p><p><i>This breakfast session is sponsored by COSA, and delivered by the COSA Nutrition and Exercise and Cancer Groups</i> </p><p><b>Best of the Best Posters – Epidemiology</b>\u0000 \u0000 </p><p>Chair: Ashley Hopkins</p><p>Discussant: Rebecca Venchiarutti</p><p>7:15 AM <b>Maria Aslam</b></p><p>Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: A population-based cohort study <i>abs# 301</i></p><p>7:20 AM <b>Vicki Durston</b></p><p>Making metastatic breast cancer count: Barriers, enablers and key recommendations identified through expert interviews and a national roundtable <i>abs# 304</i></p><p>7:25 AM <b>Lucy Gately</b></p><p>Linking data from a brain cancer clinical registry (BRAIN) with the state-based registry of Births Deaths Marriages: Improving the quality of clinical registry survival data <i>abs# 305</i></p><p>7:30 AM <b>Huah Shin Ng</b></p><p>Patterns of mental health service utilisation in people with cancer compared with people without cancer: The Australian National Study of Mental Health and Wellbeing analysis <i>abs# 312</i></p><p>7:35 AM <b>Suzanne Poulgrain</b></p><p>Patterns of treatment and survival outcomes for people diagnosed with glioblastoma: A population-based study in Queensland <i>abs# 314</i></p><p>7:40 AM <b>Robert Power</b></p><p>Modifiable risk factors for cancer among people with Lynch syndrome: An international, cross-sectional survey <i>abs# 315</i></p><p>7:45 AM <b>Euan Walpole</b></p><p>Benchmarking statewide cancer data: A comparison of breast and gynaecological cancer care indicators between Victoria and Queensland <i>abs# 316</i></p><p><i>Session sponsored by</i> </p><p><b>Best of the Best Posters – Clinical Research & Supportive Care</b>\u0000 \u0000 </p><p>Chair: Laura Kirsten</p><p>Discussant: Desmond Yip</p><p>7:15 AM <b>Morgan Farley</","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura E Anderson1,2, Katelyn Collins1,3, Larry Myers1,3, Michael J Ireland3,4, Mariam Omar1, Allanah Drummond3, Leah Zajdlewicz1, Belinda Goodwin1,4,5
1Cancer Council Queensland, Fortitude Valley, Queensland, Australia
2National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia
3School of Psychology and Wellbeing, University of Southern Queensland, Springfield, Queensland, Australia
4Centre for Health Research, University of Southern Queensland, Springfield, Queensland, Australia
5Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Queensland, Australia
Aims: Population-wide cancer screening programs save lives through early cancer detection; however, many people do not participate. We aimed to understand decision formation and prompts to action for screening behaviours to inform interventions to increase bowel, breast and cervical cancer screening uptake.
Methods: Cancer screeners (N = 962) were asked what made them decide to screen and what prompted them to act through an online survey. Content analysis was used to capture the frequency of common responses. Interrater reliability was high (κ = .96, %agree = 97%).
Results: For breast and cervical screening, decisions were commonly based on ‘screening being routine’ (32.58% – breast, 35.19% – cervical) or ‘receiving a reminder’ (20.53% – breast, 13.07% – cervical), and common prompts were ‘receiving a reminder’ (40.68% – breast, 29.13% – cervical), ‘screening being routine’ (22.05% breast, 18.65% cervical). Participants reported deciding to screen for bowel cancer due to ‘arrival of home screening test kit’ (40.50%) or the ‘experience of loved one's cancer’ (13.57%) and were prompted by ‘arrival of home test kit’ (23.58%), ‘convenience’ (15.72%) and the ‘desire to “get it over with”’ (10.22%). Importantly, approximately 25% of participants gave the same response to both the decision and prompt question.
Conclusions: Interventions should target reminders and messages that support screening as part of regular healthcare routine, particularly for breast and cervical cancer screening. For bowel cancer screening, messaging should encourage immediate use of bowel cancer screening kits upon arrival. The messaging inviting individuals to screening programs should be carefully considered, as it often coincides with both the decision to participate and prompts action.
{"title":"Poster Abstracts","authors":"","doi":"10.1111/ajco.14026","DOIUrl":"https://doi.org/10.1111/ajco.14026","url":null,"abstract":"<p>Laura E Anderson<sup>1,2</sup>, Katelyn Collins<sup>1,3</sup>, Larry Myers<sup>1,3</sup>, Michael J Ireland<sup>3,4</sup>, Mariam Omar<sup>1</sup>, Allanah Drummond<sup>3</sup>, <span>Leah Zajdlewicz</span><sup>1</sup>, Belinda Goodwin<sup>1,4,5</sup></p><p><i><sup>1</sup>Cancer Council Queensland, Fortitude Valley, Queensland, Australia</i></p><p><i><sup>2</sup>National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia</i></p><p><i><sup>3</sup>School of Psychology and Wellbeing, University of Southern Queensland, Springfield, Queensland, Australia</i></p><p><i><sup>4</sup>Centre for Health Research, University of Southern Queensland, Springfield, Queensland, Australia</i></p><p><i><sup>5</sup>Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Queensland, Australia</i></p><p><b>Aims</b>: Population-wide cancer screening programs save lives through early cancer detection; however, many people do not participate. We aimed to understand decision formation and prompts to action for screening behaviours to inform interventions to increase bowel, breast and cervical cancer screening uptake.</p><p><b>Methods</b>: Cancer screeners (<i>N</i> = 962) were asked what made them decide to screen and what prompted them to act through an online survey. Content analysis was used to capture the frequency of common responses. Interrater reliability was high (<i>κ</i> = .96, %agree = 97%).</p><p><b>Results</b>: For breast and cervical screening, decisions were commonly based on ‘screening being routine’ (32.58% – breast, 35.19% – cervical) or ‘receiving a reminder’ (20.53% – breast, 13.07% – cervical), and common prompts were ‘receiving a reminder’ (40.68% – breast, 29.13% – cervical), ‘screening being routine’ (22.05% breast, 18.65% cervical). Participants reported deciding to screen for bowel cancer due to ‘arrival of home screening test kit’ (40.50%) or the ‘experience of loved one's cancer’ (13.57%) and were prompted by ‘arrival of home test kit’ (23.58%), ‘convenience’ (15.72%) and the ‘desire to “get it over with”’ (10.22%). Importantly, approximately 25% of participants gave the same response to both the decision and prompt question.</p><p><b>Conclusions</b>: Interventions should target reminders and messages that support screening as part of regular healthcare routine, particularly for breast and cervical cancer screening. For bowel cancer screening, messaging should encourage immediate use of bowel cancer screening kits upon arrival. The messaging inviting individuals to screening programs should be carefully considered, as it often coincides with both the decision to participate and prompts action.</p><p><span>Shalmoli Bhattacharyya</span><sup>1</sup>, Sanchita Khurana<sup>1</sup>, Reena Sharma<sup>2</sup>, Bhavana Rai<sup>2</sup>, Rashmi Bagga<sup>3</sup></p><p><i><sup>1</sup>Biophysics, PGIMER, Chandigarh, India</i></p><p><i><sup>2</sup>Radiotherapy, PGIMER, Chandi","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68180145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rhett Morton1, Marcelo Nascimento2, Penny Mackenzie1, Kathryn Middleton3, Shaun McGrath3, Anna Kuchel1, Danica Cossio4, Victoria Donoghue4, Karen Sanday5, Neal Rawson4, Euan Walpole4,6, Andrea Garrett1
1Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
2Gold Coast University Hospital, Gold Coast, Queensland, Australia
3Mater Hospital Brisbane, Brisbane, Queensland, Australia
4Cancer Alliance Queensland, Wooloongabba, Queensland, Australia
5Queensland Centre for Gynaecological Cancer, Brisbane, Queensland, Australia
6Princess Alexandra Hospital, Brisbane, Queensland, Australia
Aims: To understand the patterns of treatment for gynecological cancers (GC) across Queensland between 2012 and 2021 and look for areas of improvement.
Methods: The source of population data for this study is the Queensland Oncology Repository (QOR), which is a comprehensive clinical cancer database that links diagnostic information from the Queensland Cancer Register (QCR), with treatment data (radiation therapy, surgery, and intravenous systemic therapy), admissions data for both public and private hospitals, and patient outcome data. Clinical data including FIGO stage and biomarkers was extracted from the Queensland Centre for Gynaecological Cancer database and linked to QOR.
Results: A total of 11,909 Queensland women were diagnosed with GC between 2012 and 2021. The most common diagnosis is endometrial (45%, n = 5378) followed by ovarian (29%, n = 3453) and then cervical (18%, n = 2127) with the three making up 92% of all GC.
Women with GC typically require a multidisciplinary approach to their care, including surgery, radiation therapy, and systemic therapy. The overall treatment rate is high at 88% (n = 10,423/11,909). 73% of all GC diagnoses underwent resection with endometrial cancer having the highest resection rate of 84%. Radiation therapy treatment rates were highest for cervical cancer (47%), while systemic therapy rates were highest (70%) for ovarian cancer.
Small increases in the radiation therapy treatment rate between 2012 and 2016 and 2017 and 2021 were observed for endometrial (22%–26%) and vulval (29%–35%) cancers.
Survival for GC varies across the individual primary sites with endometrial cancer survival at 5 years 78% compared to ovarian at 44%.
Conclusion: Accessing linked population-wide data enables active monitoring of care patterns for women with GC. This resource facilitates the extraction of valuable insights and evaluation of effective strategies and interventions to prevent, detect, diagnose, and treat GC.
Tamara Butler
方法：使用的数据来自关联数据集，包括医疗保险福利计划、药物福利计划、维多利亚州乳腺筛查（BSV）、维多利亚州入院发作数据集、维多利亚州放射治疗最低数据集和维多利亚州癌症登记处（VCR）。从VCR中确定了2011年至2019年间被诊断患有侵袭性癌症的50岁至69岁的女性（n=20069）。与早期检测阶段一致被定义为通过BSV诊断或在诊断前3年至90天进行非BSV乳房X光检查。使用逻辑回归和Cox风险模型的风险比计算比值比。结果：20069年中，共有11517人（57%）符合筛查建议（45%通过BSV，12%通过非BSV乳房X光检查）。SES五分位数和偏远地区之间的一致性相似。在符合条件的队列中，诊断为1期的女性比例更高（63%比30%）。校正年龄后，对齐与诊断早期相关（OR=0.26，95%CI:0.25-.28）。接受保乳手术的女性比例更高（82%对61%），在根据年龄和分期进行调整后，其持续存在（OR:.59，95%CI:.55-.64）。调整年龄和分期后，符合早期检测阶段的患者的生存率有所提高（HR:.52，95%CI:.43-.64）结论：符合OCP的筛查建议与诊断为癌症的筛查年龄女性的更好结果相关。Zoe G Gibbs1,2，Caitlin I Fox-Harding1,2，Daniel A Galvão1,2，Dennis R Taafffe1,2，Rob U Newton1,21Edith Cowan University，Joondalup，WA，Australia2Exercise Medicine Research Institute，Joondarup，WA，澳大利亚目的：我们在一项为期12周、为期4个月的随机对照试验中检查了阻力运动负荷的操作，其中评估了高负荷（HL）或低负荷（LL）训练的有效性，以完善治疗乳腺癌相关淋巴水肿（BCRL）的运动处方。参与者和方法：BCRL幸存者（n=94，年龄22-84岁，平均54岁）被随机分配到常规护理（UC，n=31）、HL（n=31）或LL（n=32）运动组。每周两次的运动包括2-4组上半身和下半身阻力运动，HL从最大8次重复（RM）发展到5次重复，LL从最大18次重复发展到15次重复，再加上有氧训练（心率最大65%-80%时，15-25分钟）。在基线、12周和4个月的随访中评估淋巴相对体积（LRV）、肌肉功能和功能表现（反复坐椅子、400米步行）。统计分析包括ANOVA和ANCOVA。结果：73名参与者完成了研究。与UC相比，HL和LL在12周的干预中均降低了LRV（HL−8.6%，LL−7.8%；p=0.001），在4个月的随访中没有进一步的显著变化。两个运动组的肌肉力量都有所改善（p=0.001），UC没有变化（胸部按压：HL 4.7 kg，LL 3.8 kg；坐排：HL 9.7 kg，LL 4.9 kg；腿部伸展：HL 5.6 kg；LL 3.9 kg），HL和LL之间没有差异。HL（−36.2秒，p=.025）和LL（−18.9秒，p=.004）在400米步行中的表现也随着锻炼而改善，与LL（p=.020）相比，HL产生了显著的改善，结论：我们证明高负荷和低负荷抵抗运动对BCRL幸存者有效治疗淋巴水肿是可行的，并且在运动后4个月内身体和功能表现都有所改善。Yada Kanjanapan1,2，Wayne Anderson3，Mirka Smith3，Jenny Green3，Elizabeth Chalker3，Paul Craft1,21澳大利亚首都堪培拉堪培拉医院肿瘤医学部2澳大利亚国立大学堪培拉3澳大利亚首都堪培拉卫生局数据分析处，澳大利亚简介：在使用不同的合格标准分别使用阿匹昔单抗和核糖昔单抗的君主试验和NATALEE试验中，使用辅助CDK4/6抑制剂加强治疗提高了无病生存率。我们评估了癌症患者在澳大利亚人群中符合这些标准的比例及其结果。方法：对ACT癌症治疗组（1997年6月-2017年6月）的连续患者进行分析。符合君主E条件的患者具有>；=4+淋巴结（LN）或1-3+LN加肿瘤>；=5 cm或3级。NATALEE还包括LN阴性>；5厘米和2.1−5厘米的3级癌症。采用卡方检验对各组进行比较；Kaplan–Meier法估计生存率。结果：在3840例激素受体阳性HER2阴性癌症患者中，718例（18.7%）符合君主E标准；2024人（52.7%）符合NATALEE资格。符合君主E条件的患者更年轻（中位数为56岁对59岁，p＜0.001），绝经前患者比例更高（34%对。 22%；0.001）。接受化疗的符合条件的患者明显增多（81%对33%，p＜0.001）。符合条件的中位总生存期较短（61个月对105个月，HR 1.89，95%CI:1.60–2.22，p＜001）。符合NATALEE条件的患者更有可能在绝经前接受更高的化疗（66%对16%）。淋巴结阴性患者占符合NATALEE条件的队列的31%，而符合NATALE条件的LN阴性患者占26%。符合NATALEE条件的患者的生存率低于不符合条件的患者，中位数为78个月对106个月（HR 1.36，95%CI:1.16–1.59，p<；0.001）。在符合NATALE条件的患者中，65%（n=1306），即34%的研究人群不符合君主制。符合这两项研究标准的患者的生存率低于仅符合NATALEE标准的患者（中位数61个月vs.96个月，HR 1.78，95%CI:1.47-2.14，p<；0.001）。Antonia Pearson 1，2，Haryana Dhillon3，Jill Chen3，Janine Lombard4，5，6，Martha Hickey7，8，Belinda Kiely 9，10111新南威尔士州Frenchs Forest的Northhern Beaches医院，澳大利亚2悉尼大学，Camperdown，澳大利亚3医学心理学中心；基于证据的决策，悉尼大学理学院心理学院，澳大利亚坎珀敦4纽卡斯尔私立医院，澳大利亚纽卡斯尔5医学肿瘤学，Calvary Mater Newcastle，澳大利亚纽卡斯尔6纽卡斯尔大学，澳大利亚纽卡斯尔7墨尔本大学，墨尔本8妇产科；澳大利亚墨尔本皇家女子医院妇科9NHMRC临床试验中心，悉尼大学，澳大利亚坎珀敦10澳大利亚坎珀镇癌症治疗中心11澳大利亚康科德癌症中心康科德遣返综合医院康科德，澳大利亚目的：我们旨在提高对癌症（BC）女性泌尿生殖系统症状（GUS）的认知和体验的理解。方法：来自9家新南威尔士州癌症服务机构和癌症网络澳大利亚成员的肿瘤诊所参与者完成了一项调查，内容涉及GUS的类型和影响，以及对治疗方案的看法。结果：505名妇女完成了调查：平均年龄59岁（30-83岁）；52%目前性活跃；58%目前正在接受内分泌治疗；84%为早期BC。70%的受访者报告患有GUS，少数人报告因此改变（5%）或停止（4%）内分泌治疗。阴道干燥是最常见的症状（62%），其次是穿刺疼痛（41%）和瘙痒（33%）。只有38%的受访者回忆起他们的癌症医生曾警告过GUS可能是B
{"title":"Oral Abstracts","authors":"","doi":"10.1111/ajco.14025","DOIUrl":"https://doi.org/10.1111/ajco.14025","url":null,"abstract":"<p><span>Rhett Morton</span><sup>1</sup>, Marcelo Nascimento<sup>2</sup>, Penny Mackenzie<sup>1</sup>, Kathryn Middleton<sup>3</sup>, Shaun McGrath<sup>3</sup>, Anna Kuchel<sup>1</sup>, Danica Cossio<sup>4</sup>, Victoria Donoghue<sup>4</sup>, Karen Sanday<sup>5</sup>, Neal Rawson<sup>4</sup>, Euan Walpole<sup>4,6</sup>, Andrea Garrett<sup>1</sup></p><p><i><sup>1</sup>Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia</i></p><p><i><sup>2</sup>Gold Coast University Hospital, Gold Coast, Queensland, Australia</i></p><p><i><sup>3</sup>Mater Hospital Brisbane, Brisbane, Queensland, Australia</i></p><p><i><sup>4</sup>Cancer Alliance Queensland, Wooloongabba, Queensland, Australia</i></p><p><i><sup>5</sup>Queensland Centre for Gynaecological Cancer, Brisbane, Queensland, Australia</i></p><p><i><sup>6</sup>Princess Alexandra Hospital, Brisbane, Queensland, Australia</i></p><p><b>Aims</b>: To understand the patterns of treatment for gynecological cancers (GC) across Queensland between 2012 and 2021 and look for areas of improvement.</p><p><b>Methods</b>: The source of population data for this study is the Queensland Oncology Repository (QOR), which is a comprehensive clinical cancer database that links diagnostic information from the Queensland Cancer Register (QCR), with treatment data (radiation therapy, surgery, and intravenous systemic therapy), admissions data for both public and private hospitals, and patient outcome data. Clinical data including FIGO stage and biomarkers was extracted from the Queensland Centre for Gynaecological Cancer database and linked to QOR.</p><p><b>Results: </b> A total of 11,909 Queensland women were diagnosed with GC between 2012 and 2021. The most common diagnosis is endometrial (45%, <i>n</i> = 5378) followed by ovarian (29%, <i>n</i> = 3453) and then cervical (18%, <i>n</i> = 2127) with the three making up 92% of all GC.</p><p>Women with GC typically require a multidisciplinary approach to their care, including surgery, radiation therapy, and systemic therapy. The overall treatment rate is high at 88% (<i>n</i> = 10,423/11,909). 73% of all GC diagnoses underwent resection with endometrial cancer having the highest resection rate of 84%. Radiation therapy treatment rates were highest for cervical cancer (47%), while systemic therapy rates were highest (70%) for ovarian cancer.</p><p>Small increases in the radiation therapy treatment rate between 2012 and 2016 and 2017 and 2021 were observed for endometrial (22%–26%) and vulval (29%–35%) cancers.</p><p>Survival for GC varies across the individual primary sites with endometrial cancer survival at 5 years 78% compared to ovarian at 44%.</p><p><b>Conclusion: </b> Accessing linked population-wide data enables active monitoring of care patterns for women with GC. This resource facilitates the extraction of valuable insights and evaluation of effective strategies and interventions to prevent, detect, diagnose, and treat GC. </p><p><span>Tamara Butler</sp","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68180718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"COSA committees","authors":"","doi":"10.1111/ajco.14018","DOIUrl":"10.1111/ajco.14018","url":null,"abstract":"<p>\u0000 \u0000 </p><p>A/Professor Dion Forstner – President</p><p>Professor Sabe Sabesan – President Elect</p><p>Ms Sandie Angus</p><p>Professor Judy Bauer</p><p>Professor Tanya Buchanan</p><p>Clinical A/Professor Merran Findlay (commenced March 2023)</p><p>Mr Peter Hooker</p><p>Dr Malinda Itchins</p><p>Professor Michael Jefford</p><p>Professor Tim Price</p><p>A/Professor Christopher Steer</p><p>A/Professor Dion Forstner – President</p><p>Professor Sabe Sabesan – President Elect</p><p>Professor Fran Boyle AM – Immediate Past President</p><p>Professor Meera Agar – Geriatric Oncology</p><p>A/Professor Arun Azad – Urologic Oncology</p><p>Ms Kathy Bell – Consumer Representative</p><p>Dr David Chan – Neuroendocrine Tumours</p><p>Professor Raymond Chan – Cancer Survivorship</p><p>Dr Connie Diakos – Gastrointestinal Cancer</p><p>Dr Susan Fraser – Breast Cancer</p><p>Professor Gail Garvey – First Nations Representative</p><p>Dr Ashley Hopkins – Epidemiology</p><p>Dr Malinda Itchins – Lung Cancer</p><p>Dr Laura Kirsten – Psycho-Oncology</p><p>Dr Andrea Knox – Advanced Trainee Representative (resigned April 2023)</p><p>Ms Merran Findlay – Nutrition (resigned March 2023)</p><p>Dr Eng-Siew Koh – Neuro-Oncology</p><p>Dr Judith Lacey – Integrative Oncology</p><p>Dr Wei-Sen Lam – Regional and Rural</p><p>Ms Jenelle Loeliger – Nutrition (commenced April 2023)</p><p>A/Professor Alex Menzies – Melanoma and Skin Cancer (resigned March 2023)</p><p>Professor Linda Mileshkin – Gynaecological Cancer</p><p>Dr David Mizrahi – Exercise and Cancer</p><p>Dr Wayne Nicholls – Adolescent and Young Adult</p><p>Dr Sophie Nightingale – Surgical Oncology</p><p>Professor Jane Phillips – Palliative Care</p><p>Ms Marissa Ryan – Cancer Pharmacists (Co-Chair)</p><p>Dr Geeta Sandhu – Cancer Pharmacists (Co-Chair)</p><p>Professor Clare Scott AM – Rare Cancers</p><p>Professor Bernard Stewart AM – Cancer Prevention</p><p>Mr Adam Stoneley – Clinical Trials and Research Professionals</p><p>Mr Simon Troth – Cancer Genetics</p><p>Dr Paul Viray – Advanced Trainee Representative (commenced June 2023)</p><p>Distinguished Professor Patsy Yates AM – Cancer Care Coordination</p><p>Professor Desmond Yip – Global Oncology</p><p>Ms Leonie Young – Consumer Representative</p><p>Professor Nik Zeps – Cancer Biology</p><p>Ms Marie Malica – Chief Executive Officer</p><p>Australasian Gastro-Intestinal Trials Group – Professor Tim Price</p><p>Australasian Leukaemia & Lymphoma Group – Professor Judith Trotman</p><p>Australia & New Zealand Sarcoma Association – Professor Angela Hong</p><p>Australian and New Zealand Children's Haematology/Oncology Group – Dr Nick Gottardo</p><p>Australia New Zealand Gynaecology Oncology Group – Professor Clare Scott AM</p><p>Australia and New Zealand Head & Neck Cancer Society – Dr Tsien Fua</p><p>Australia and New Zealand Urogenital & Prostate Cancer Trials Group – Professor Ian Davis</p><p>Breast Cancer Trials – Professor Sunil Lakhani</p><p>Cancer","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dr George Au-Yeung is a clinician-researcher at Peter MacCallum Cancer Centre, and has a research interests in molecular biology of ovarian cancer as well as running novel biomarker driven clinical trials and translational research. He completed his PhD in Professor David Bowtell's laboratory, investigating novel therapeutic strategies for Cyclin E1 amplified high grade serous ovarian cancer, a subset of ovarian cancers that behave aggressively and lack treatment options. He is now a full-time medical oncologist at Peter Mac, working across the Gynae-Oncology and Melanoma service, and is Co-Deputy Director of Medical Oncology. He is an active member of ANZGOG, and holds current and former positions with the Royal Australasian College of Physicians (RACP) and the Medical Oncology Group of Australia (MOGA).
Kira Bloomquist
Griffith University, UCSF, Copenhagen University Hospital
I am a physical therapist and research fellow, currently affiliated with the University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, Denmark and Menzies Health Institute Queensland, Griffith University. My main areas of interest relate to “cancer survivorship” and draw on personal hands-on experiences with cancer survivors as a physical therapist since 1999, as well as experiences gained while undertaking various research roles (e.g., data collector, research assistant, and primary investigator) since 2003. My specific expertise relates to understanding the physical and psychosocial concerns faced following cancer, in particular lymphedema, and the role of exercise in cancer recovery.
A/Prof Anna Boltong
Cancer Australia
Associate Professor Anna Boltong is the Head of the Cancer Control Strategy Branch at Cancer Australia. A dietitian by training, Anna's background spans domestic and international leadership in clinical oncology, supportive care research, policy development, health inequalities, and education. At Cancer Australia, Anna oversees the development and implementation of the Australian Cancer Plan as well as the Optimal Care Systems and Indigenous Cancer Control portfolios.
A/Prof Angie Bone
Monash University
Angie is an Associate Professor of Practice in planetary health at the Monash Sustainable Development Institute, where she focuses on system transformation for health sector resilience and sustainability, behaviour change and planetary health. She is a senior public health physician and former Deputy Chief Health Officer in Victoria, with over 15 years of public health leadership and research experience on environmental influences on health and health equity. Angie works with a range of disciplines across the research/policy/practice interface, providing public health technical expertise combined with policy and
{"title":"National speakers","authors":"","doi":"10.1111/ajco.14021","DOIUrl":"10.1111/ajco.14021","url":null,"abstract":"<p></p><p><b>Dr George Au-Yeung</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr George Au-Yeung is a clinician-researcher at Peter MacCallum Cancer Centre, and has a research interests in molecular biology of ovarian cancer as well as running novel biomarker driven clinical trials and translational research. He completed his PhD in Professor David Bowtell's laboratory, investigating novel therapeutic strategies for Cyclin E1 amplified high grade serous ovarian cancer, a subset of ovarian cancers that behave aggressively and lack treatment options. He is now a full-time medical oncologist at Peter Mac, working across the Gynae-Oncology and Melanoma service, and is Co-Deputy Director of Medical Oncology. He is an active member of ANZGOG, and holds current and former positions with the Royal Australasian College of Physicians (RACP) and the Medical Oncology Group of Australia (MOGA).</p><p></p><p><b>Kira Bloomquist</b></p><p><i>Griffith University, UCSF, Copenhagen University Hospital</i></p><p>I am a physical therapist and research fellow, currently affiliated with the University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, Denmark and Menzies Health Institute Queensland, Griffith University. My main areas of interest relate to “cancer survivorship” and draw on personal hands-on experiences with cancer survivors as a physical therapist since 1999, as well as experiences gained while undertaking various research roles (e.g., data collector, research assistant, and primary investigator) since 2003. My specific expertise relates to understanding the physical and psychosocial concerns faced following cancer, in particular lymphedema, and the role of exercise in cancer recovery.</p><p></p><p><b>A/Prof Anna Boltong</b></p><p><i>Cancer Australia</i></p><p>Associate Professor Anna Boltong is the Head of the Cancer Control Strategy Branch at Cancer Australia. A dietitian by training, Anna's background spans domestic and international leadership in clinical oncology, supportive care research, policy development, health inequalities, and education. At Cancer Australia, Anna oversees the development and implementation of the Australian Cancer Plan as well as the Optimal Care Systems and Indigenous Cancer Control portfolios.</p><p></p><p><b>A/Prof Angie Bone</b></p><p><i>Monash University</i></p><p>Angie is an Associate Professor of Practice in planetary health at the Monash Sustainable Development Institute, where she focuses on system transformation for health sector resilience and sustainability, behaviour change and planetary health. She is a senior public health physician and former Deputy Chief Health Officer in Victoria, with over 15 years of public health leadership and research experience on environmental influences on health and health equity. Angie works with a range of disciplines across the research/policy/practice interface, providing public health technical expertise combined with policy and","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
TOM REEVE AWARD FOR OUTSTANDING CONTRIBUTIONS TO CANCER CARE
This respected award, offered by COSA, formally recognises a national leader who has made a significant contribution over a relatively long period toward cancer care through research, clinical leadership, and/or community service. The award presentation and recipient's oration highlighting an overview of career achievements will be delivered Thursday 2 November at 1:30 pm.
COSA is proud to announce the 2023 recipient of the Tom Reeve Award for outstanding contributions to cancer care is Dr David Speakman OAM.
Past recipients include:
2022 Professor John Thompson AO
2021 Professor Michael Barton OAM
2020 Professor Sanchia Aranda AM
2019 Professor Ian Olver AM
2018 Professor Grant McArthur
2017 Emeritus Professor William H. McCarthy AM
2016 Professor Fran Boyle AM
2015 Professor David Currow
2014 Professor John Zalcberg OAM
2013 Professor Ian Frazer AC
2012 Professor David Ball AO
2011 Professor Phyllis Butow AM
2010 Professor John Forbes AM
2009 Professor Patsy Yates AM
2008 Professor Lester Peters AM
2007 Professor Martin Tattersall AO
2006 Professor Alan Coates AM
2005 (Inaugural Award) Professor Tom Reeve AC CBE
Tom Reeve AC CBE was Emeritus Professor in Surgery of the University of Sydney, graduating in 1947. After working in Sydney and North Queensland, he went to Albany Medical College, upstate New York to complete training in General and Thoracic Surgery. In 1958, Prof. Reeve became certified with the American Board of Surgery and in 1967 became a Fellow of the Royal Australasian College of Surgeons. He was Chairman of Surgery at The University of Sydney from 1982 to 1988 and chaired the Northern Sydney Health Area from 1988 to 1996. On retirement, Prof. Reeve became President of the Royal Australasian College of Surgeons and was appointed Executive Officer of the Australian Cancer Network in late 1993. In this role, Prof. Reeve was involved in the development of Best Practice Guidelines in Cancer Management and the development of “Clinical Guidelines for the Management of Early Breast Cancer” for the NHMRC. These were the first evidence-based cancer management guidelines produced in Australia. Tom was a member of the Boards of Management of the NHMRC National Breast Cancer Centre and the National Cancer Control Initiative.
It was with great sadness that we learnt of the passing of Tom on August 20, 2023. This year's Tom Reeve Award and oration at the ASM will carry an additional poignancy.
3:00 pm, Friday 3 November
The COSA Presidential Lecture was introduced in 2010 and is an opportunity for our organisation to recognise the contribution of an individual to medical research, and for the COSA membership to be informed of and learn about that individual's work. COSA is delighted that Professor Bogda Ko
TOM REEVE癌症护理杰出贡献奖由COSA颁发的这一备受尊敬的奖项正式表彰了一位在相对较长的一段时间内通过研究、临床领导和/或社区服务为癌症护理做出重大贡献的国家领导人。颁奖典礼和获奖者演讲将于11月2日星期四下午1:30发表，重点介绍职业成就。OSA很荣幸地宣布，2023年因对癌症护理做出杰出贡献而获得Tom Reeve奖的是David Speakman OAM博士。过去的获奖者包括：2022年John Thompson AO2021教授Michael Barton OAM2020教授Sanchia ArandaAM2019 Ian Olver教授AM2018 Grant McArthur教授2017名誉教授William H。McCarthy AM2016 Fran Boyle教授AM2015 David Currow教授2014 John Zalcberg教授OAM2013 Ian Frazer AC2012 David Ball教授AO2011 Phyllis Butow教授AM2010 John Forbes教授AM2009 Patsy Yates教授AM2008 Lester Peters教授AM2007 Martin Tattersall教授AO2006 Alan Coates教授AM2005（就职奖）Tom Reeve教授AC CBETom ReeveAC CBE是悉尼大学外科名誉教授，1947年毕业。在悉尼和北昆士兰工作后，他去了纽约州北部的奥尔巴尼医学院，完成了普通外科和胸外科的培训。1958年，里夫教授获得了美国外科委员会的认证，并于1967年成为澳大利亚皇家外科学院的院士。1982年至1988年，他担任悉尼大学外科主任，1988年至1996年担任北悉尼卫生区主任。退休后，Reeve教授成为澳大利亚皇家外科学院院长，并于1993年末被任命为澳大利亚癌症网络的执行官。在这个职位上，Reeve教授参与了癌症管理最佳实践指南的制定和NHMRC“早期癌症管理临床指南”的制定。这是澳大利亚制定的第一份基于证据的癌症管理指南。汤姆是NHMRC国家癌症中心和国家癌症控制倡议管理委员会的成员。我们怀着极大的悲伤得知汤姆于2023年8月20日去世。今年的Tom Reeve奖和在ASM上的演讲将带来额外的辛酸。11月3日星期五下午3:00 COSA总统演讲于2010年推出，这是我们组织表彰个人对医学研究的贡献的机会，也是COSA成员了解和了解个人工作的机会。COSA很高兴Bogda Koczwara AM教授接受邀请出席COSA总统演讲。Koczwara教授将为许多COSA成员所熟知，他曾在该组织中担任过许多杰出的角色，最著名的是担任前任主席（2011-2012年）、幸存者小组前任主席和COSA-Flinders癌症幸存者会议召集人。还是这样？结束COSA第50届ASM的合适方式。过去的演讲者包括：2022尊敬的Greg Hunt2021获奖教授Peter Doherty AC2020 Ian Frazer AC2019 Kirk Pengilly 2018 Tim Hammond 2017 Richard De Crespigny 2016 Ranjana Srivastava OAM2015 Mark Dawson 2014 Jim Bishop AO2013 Ian Maddocks AM2012 Ian Fra泽AC2011 Barry Marshall教授AC2010（就职演讲）荣休教授Donald Metcalfe ACE每年COSA都会颁发“最佳中的最佳”口头和海报讨论奖。奖项是在一个竞争性的、独立的过程中颁发的，所有学科都可以获得。这是一个建立COSA全球形象的大好机会，也是一个奖励我们在基于知识的癌症临床护理方面做出卓越贡献的多样化会员的大好机会。根据演讲的内容、创新程度和重要性以及质量，每个“最佳中的最佳”口头和海报讨论类别都会获得奖项。“最佳中的最佳”口头奖在每个类别中平均价值1000.00美元。“最佳中的最佳”海报讨论奖在每个类别中平均价值500.00美元。
{"title":"Highlighted lectures and awards 2023","authors":"","doi":"10.1111/ajco.14019","DOIUrl":"10.1111/ajco.14019","url":null,"abstract":"<p><b>TOM REEVE AWARD FOR OUTSTANDING CONTRIBUTIONS TO CANCER CARE</b></p><p>This respected award, offered by COSA, formally recognises a national leader who has made a significant contribution over a relatively long period toward cancer care through research, clinical leadership, and/or community service. The award presentation and recipient's oration highlighting an overview of career achievements will be delivered Thursday 2 November at 1:30 pm.</p><p>COSA is proud to announce the 2023 recipient of the Tom Reeve Award for outstanding contributions to cancer care is <b>Dr David Speakman OAM</b>.</p><p>Past recipients include:</p><p>2022 Professor John Thompson AO</p><p>2021 Professor Michael Barton OAM</p><p>2020 Professor Sanchia Aranda AM</p><p>2019 Professor Ian Olver AM</p><p>2018 Professor Grant McArthur</p><p>2017 Emeritus Professor William H. McCarthy AM</p><p>2016 Professor Fran Boyle AM</p><p>2015 Professor David Currow</p><p>2014 Professor John Zalcberg OAM</p><p>2013 Professor Ian Frazer AC</p><p>2012 Professor David Ball AO</p><p>2011 Professor Phyllis Butow AM</p><p>2010 Professor John Forbes AM</p><p>2009 Professor Patsy Yates AM</p><p>2008 Professor Lester Peters AM</p><p>2007 Professor Martin Tattersall AO</p><p>2006 Professor Alan Coates AM</p><p>2005 (Inaugural Award) Professor Tom Reeve AC CBE</p><p></p><p><b>Tom Reeve AC CBE</b> was Emeritus Professor in Surgery of the University of Sydney, graduating in 1947. After working in Sydney and North Queensland, he went to Albany Medical College, upstate New York to complete training in General and Thoracic Surgery. In 1958, Prof. Reeve became certified with the American Board of Surgery and in 1967 became a Fellow of the Royal Australasian College of Surgeons. He was Chairman of Surgery at The University of Sydney from 1982 to 1988 and chaired the Northern Sydney Health Area from 1988 to 1996. On retirement, Prof. Reeve became President of the Royal Australasian College of Surgeons and was appointed Executive Officer of the Australian Cancer Network in late 1993. In this role, Prof. Reeve was involved in the development of Best Practice Guidelines in Cancer Management and the development of “Clinical Guidelines for the Management of Early Breast Cancer” for the NHMRC. These were the first evidence-based cancer management guidelines produced in Australia. Tom was a member of the Boards of Management of the NHMRC National Breast Cancer Centre and the National Cancer Control Initiative.</p><p>It was with great sadness that we learnt of the passing of Tom on August 20, 2023. This year's Tom Reeve Award and oration at the ASM will carry an additional poignancy.</p><p>3:00 pm, Friday 3 November</p><p>The COSA Presidential Lecture was introduced in 2010 and is an opportunity for our organisation to recognise the contribution of an individual to medical research, and for the COSA membership to be informed of and learn about that individual's work. COSA is delighted that Professor Bogda Ko","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号